IMNM Q3 2023 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$3M95.3% margin

Operating Income

-$5M-130.0% margin

Net Income

-$4M-121.9% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-16.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$93M

Total Liabilities

$87M

Stockholders' Equity

$6M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$5M	-$9M	+45.7%
Net Income	-$4M	-$9M	+49.1%